FOR IMMEDIATE RELEASE November 5, 2026
Maintaining Pro Forma Adjusted Constant Currency Revenue Growth Guidance Range of 3.5% to 4.5%
Increasing 2026 Adjusted Diluted EPS from Continuing Operations Guidance Range to $7.50 to $7.75
Repurchased $350 Million in Common Stock Through Accelerated Share Repurchase and Open-Market Transactions Since July 1, 2026
Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 30, 2026.
• Revenue from continuing operations of $567.8 million, up 0.2% compared to the prior year period, and up 3.0% on a pro forma adjusted constant currency basis 1,2
• GAAP diluted EPS from continuing operations of $1.30, compared to $(1.32) in the prior year period
• Adjusted diluted EPS from continuing operations of $2.63, compared to $1.89 in the prior year period
“We are pleased with our third quarter performance, which included margin expansion and robust earnings per share growth, even when excluding IEEPA tariff refunds,” said Jason Weidman, Teleflex’s President and Chief Executive Officer. “Vascular and Surgical continued to deliver solid mid-single-digit growth, and Interventional improved, returning to modest growth. We made notable progress on the Interventional integration and strengthened the business’s leadership with the addition of Jason Fontana as President and General Manager. We also reached an important milestone in simplifying our operating model: we now manage and report as three global business units, Vascular, Interventional and Surgical. Reflecting our third quarter progress, we are raising our full-year adjusted earnings per share guidance.”
Mr. Weidman continued, “We also continued to return capital to shareholders on an accelerated timeline, repurchasing approximately $350 million of common stock between the beginning of the third quarter and the issuance of this release, through the completion of our $250 million accelerated share repurchase program and an additional $100 million in open-market purchases. We remain confident in completing the Acute Care and Interventional Urology divestiture and continue to work toward closing by year-end, subject to completion of the regulatory process. At the same time, we continue to invest in innovation, with programs that have potential to become long-term growth platforms. Freesolve™, our resorbable magnesium scaffold, received FDA Breakthrough Device Designation for PCI, and we see EZPLAZ, the first and only FDA-licensed freeze-dried plasma, as a potential long-term U.S. market opportunity of at least $200 million. Our priorities are clear: strengthening our foundation by delivering our transformation, inclusive of the completion of our Strategic Divestitures and the Vascular Intervention integration, accelerating our organizational effectiveness, and elevating our growth profile within a 1 balanced capital allocation framework. We expect these efforts to deliver a meaningful step-up in adjusted earnings per share in 2027, and provide a solid foundation for sustainable growth over time.”
• Reducing GAAP revenue growth guidance range to 13.2% to 14.2% due to changes in foreign exchange rates
• Maintaining pro forma adjusted constant currency revenue growth guidance range of 3.5% to 4.5% 2
• Increasing GAAP EPS from continuing operations guidance range to $2.84 to $3.09
• Increasing Adjusted diluted EPS from continuing operations guidance range to $7.50 to $7.75
◦ Includes an assumption of approximately 20.0% (as compared to approximately 19.0% previously) adjusted operating margin for 2026 inclusive of IEEPA tariff refunds of $16.5 million recognized in the third quarter 2026
◦ Excludes expected benefits from transition services and manufacturing services agreements that come into effect upon closing the Acute Care and Interventional Urology Strategic Divestiture
◦ Reflects execution of capital allocation strategy including repayment of $700 million Term Loan A-2, reduction of revolving credit facility borrowings, and $600 million of share repurchases, consisting of $250 million of open-market repurchases completed in the second quarter of 2026 and, subsequently through the date of this release, a $250 million accelerated share repurchase and an additional $100 million of open-market repurchases
◦ Excludes other potential future repurchases under previously announced $1 billion share repurchase program primarily funded with proceeds from the Strategic Divestitures
◦ Excludes incremental debt paydown with net proceeds from the Strategic Divestitures
(1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations beginning in the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the “Strategic Divestitures".
(2) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment, (b) the impact of the Italian payback measure, and (c) the impact of foreign exchange.
As previously disclosed, on August 3, 2026, the Company completed the divestiture of its OEM business to Montagu and Kohlberg, for $1.5 billion in cash. The Company received after-tax proceeds of $1.25 billion.
The Company continues to advance the pending sale of its Acute Care and Interventional Urology businesses to Intersurgical Ltd., and the regulatory review process is progressing. The Company continues to work toward completing the transaction by the end of 2026. Timing remains subject to regulatory approval and other customary closing conditions, and closing may extend into 2027. 2
In August 2026, following the completion of the OEM sale, the Company applied a portion of the net cash proceeds to repay its $700 million term loan A-2 and a portion of its outstanding revolving credit facility borrowings.
As previously disclosed, on December 9, 2025, the Board of Directors authorized a share repurchase program for up to $1 billion of the Company's common stock. From July 1, 2026 through the date of this release, the Company has repurchased $350 million of its common stock through an ASR program and open-market purchases. This consisted of 2.7 million shares repurchased at an average price of $128.96 per share. These repurchases (but not any potential future repurchases) have been taken into account in our 2026 Continuing Operations Outlook below.
As of November 5, 2026, the Company had $400 million remaining available under the current authorization.
Following the U.S. Supreme Court’s February 20, 2026 decision invalidating tariffs imposed under the International Emergency Economic Powers Act (“IEEPA”), the Company submitted refund requests for IEEPA tariffs it had previously paid. During the third quarter of 2026, the Company received approval and payment for substantially all submitted requests, with total refund payments of $39.2 million, including refunds related to products associated with the Strategic Divestiture businesses.
Of the total refund payments, the Company recognized a benefit of $25.3 million within continuing operations, which reduced cost of sales. This benefit includes $16.5 million and $8.8 million related to tariffs recognized in 2026 and 2025, respectively. The refund pertaining to tariffs incurred in 2026 is included in the Company’s non-GAAP financial measures for the third quarter of 2026. Conversely, the refund pertaining to tariffs incurred in 2025 was excluded from the Company’s non-GAAP financial measures for the third quarter of 2026 because it does not represent normal, recurring operating expenses, making it difficult to contribute to a meaningful evaluation of our period-over-period operating performance. The Company anticipates submitting additional refund requests during the fourth quarter under the final phase of the IEEPA tariff refund process.
On September 8, 2026, the Company announced the appointment of Sean M. Salmon to its Board of Directors. Mr. Salmon brings more than three decades of global leadership experience in the medical device and pharmaceutical industries, including more than 20 years at Medtronic plc, where he most recently served as Executive Vice President and President of its Cardiovascular Portfolio, a global business with fiscal 2025 revenue of approximately $12.5 billion. Mr. Salmon also serves on the Board's Growth and Operating Committee, which was established earlier this year to support management's execution of Teleflex's strategic transformation. With Mr. Salmon's appointment, one-third of the Board has been refreshed in 2026. 3
During the third quarter of 2026, we changed our reportable segments from a geographically based presentation to a global (product based) business unit presentation. As a result, we now have the following three reportable segments: Vascular, Interventional, and Surgical. All prior comparative periods presented have been restated to reflect these changes.
The following tables provide information regarding net revenues in each of the Company's reportable operating segments for the three and nine months ended September 30, 2026 and the comparable prior year period on both a GAAP and pro forma adjusted constant currency basis.
Notes: (1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments.
(3) In 2025, amounts reflect the impact from decreases in our reserves related to the Italian payback measure pertaining to prior years.
See Pro Forma Adjusted Revenue by Segment table for reconciliation of adjustments.
The following table provides information regarding net revenues in each of the Company's reportable operating segments by region for the three and nine months ended September 30, 2026 and the comparable prior year period on a GAAP basis. 4
Note: (1) Represents Segment Net Revenues, which excludes "Other". See table above for reconciliation of Segment Net Revenues to Consolidated Net Revenues. 5
• Depreciation expense, amortization of intangible assets and deferred financing charges for the nine months ended September 30, 2026 totaled $159.4 million compared to $127.3 million for the prior year period.
• Total cash, cash equivalents and restricted cash equivalents at September 30, 2026 were $444.3 million compared to $402.7 million at December 31, 2025.
• Net accounts receivable at September 30, 2026 were $379.6 million compared to $345.6 million at December 31, 2025.
• Inventories at September 30, 2026 were $384.4 million compared to $404.4 million at December 31, 2025.
On a GAAP basis, the Company reduced its full year 2026 revenue growth from continuing operations outlook to a range of 13.2% to 14.2%. The change in guidance range reflects our updated estimate of an approximately 0.5% positive impact of foreign exchange rate fluctuations versus approximately 0.7% previously. On a pro forma adjusted constant currency basis, the Company maintained its full year 2026 revenue growth from continuing operations outlook range of 3.5% to 4.5%.
The Company increased its full year 2026 GAAP diluted earnings per share from continuing operations outlook to a range of $2.84 to $3.09. The Company increased its full year 2026 adjusted diluted earnings per share from continuing operations outlook to a range of $7.50 to $7.75.
Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation
2025 2026 Guidance Low High GAAP revenue $1,992.7 $2,256 $2,276 Vascular Intervention pro forma 199.0 — — adjustment Discontinued product -14.3 — — adjustment Italian payback -9.0 — — measure adjustment Pro forma adjusted $2,168.4 $2,256 $2,276 revenue
Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From Continuing Operations Reconciliation
Low High Forecasted 2026 GAAP revenue growth 13.2% 14.2% Vascular Intervention pro forma 10.0% 10.0% adjustment Discontinued product adjustment (0.7)% (0.7)% Italian payback measure adjustment (0.5)% (0.5)% Base year adjustment (GAAP versus pro 0.4% 0.4% forma adjusted) Estimated impact of foreign currency 0.5% 0.5% exchange rate fluctuations Forecasted 2026 pro forma adjusted 3.5% 4.5% constant currency revenue growth
6 Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation
Low High Forecasted GAAP diluted earnings per $2.84 $3.09 share from continuing operations Restructuring and optimization items, $0.93 $0.93 net of tax Acquisition, integration and divestiture $0.58 $0.58 related items, net of tax Other items, net of tax $(0.46) $(0.46) ERP implementation, net of tax $0.31 $0.31 MDR, net of tax $0.02 $0.02 Intangible amortization expense, net of $2.78 $2.78 tax Tax adjustments $0.50 $0.50 Forecasted adjusted diluted earnings per share from continuing operations, net of $7.50 $7.75 tax
A webcast of Teleflex's third quarter 2026 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on November 5, 2026.
An audio replay of the investor call will be available beginning at 11:00 am ET on November 5, 2026 , either on the Teleflex website or by telephone. The call can be accessed by dialing 1 833 309 1852 (U.S. and Canada) or 1 929 828 5978(all other locations). The confirmation code is 893 259 060.
References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.
In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.
Pro forma adjusted revenue and pro forma adjusted constant currency revenue growth give effect to, among other things, our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. The pro forma information is presented for informational purposes only and is not necessarily indicative of the historical results that would have occurred under our ownership and management, nor the results that may be obtained in the future.
Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.
We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP”. In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: pro forma adjusted revenues, pro forma adjusted constant currency revenue growth, and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.
Pro forma adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to (i) exclude products discontinued in the year ended December 31, 2025 due to a strategic realignment; (ii) exclude the items described in 8 Italian payback measure; and (iii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025.
Pro forma adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.
Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.
Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These charges include qualified restructuring costs (which may include costs associated with employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges.
Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.
Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities. 9 S eparation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed.
Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis. In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis. The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance.
Other - These are discrete items that occur sporadically and can affect period- to-period comparisons.
European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).
Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non- competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions. 10 ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.
Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.
The following table provides information regarding pro forma adjusted revenues in each of the Company's reportable operating segments in continuing operations for the three and nine months ended September 30, 2026 and the comparable prior year periods .
11 Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)
Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.
(2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues.
For the three months ended September 30, 2026, a pre-tax restructuring benefit of $0.3 million was offset by restructuring related charges of $4.0 million. For the three months ended September 28, 2025, pre-tax restructuring charges were $1.6 million and restructuring related charges were $3.3 million. For the nine months ended September 30, 2026, pre-tax restructuring charges were $16.7 million and restructuring related charges were $25.9 million. For the nine months ended September 28, 2025, pre-tax restructuring charges were $4.3 million, restructuring related charges were $11.5 million, and product optimization charges were $2.6 million.
(B) Acquisition, integration and divestiture related items – For the three and nine months ended September 30, 2026, these charges primarily related to the acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG. For the three months ended September 30, 2026 these charges included acquisition and integration costs of $4.2 million. For the nine months ended September 30, 2026 these charges included acquisition and integration costs of $20.9 million and inventory step up costs of $8.0 million. For the three and nine months ended September 28, 2025, these charges primarily related to the acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG and changes in the estimated fair value of our contingent consideration liabilities. For the three months ended September 28, 2025 the charges included inventory step-up costs of $42.1 million and integration and acquisition costs of $4.4 million. For the nine months ended September 28, 2025 the charges included inventory step-up costs of $42.1 million and acquisition and integration costs of $26.5 million, which were offset by a benefit of $82.2 million related to non-designated foreign currency forward contracts. (C)
For the three months ended September 30, 2026, other items included a benefit from IEEPA tariff refunds of $8.8 million partially offset by legal and advisory fees incurred in response to an activist investor campaign of $0.1 million and a loss on extinguishment of debt of $3.4 million. For the nine months ended September 30, 2026, other items included a benefit from a litigation settlement of $25.0 million and IEEPA tariff refunds of $8.8 million partially offset by legal and advisory fees incurred in response to an activist investor campaign of $3.7 million, a loss on extinguishment of debt of $4.5 million, and charges incurred in connection with the credit agreement refinancing of $1.0 million. 14
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.
This press release contains forward-looking statements, including, but not limited to, the implementation and execution of our share repurchase program; our intended use of proceeds from the OEM divestiture; our expectations with respect to our financial profile in 2027 and beyond; forecasted 2026 GAAP and pro forma adjusted revenue, GAAP and pro forma adjusted constant currency revenue growth and GAAP and adjusted diluted earnings per share; and our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2026 financial results. Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; the possibility that the remaining pending transaction in our Strategic Divestitures does not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the Strategic Divestitures; customer and shareholder reaction to the Strategic Divestitures; disruption from the Strategic Divestitures that may make it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; risks relating to the activities of activist stockholders; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation. 15
September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -Dollars in thousands ASSETS Current assets Cash and cash $ 430,465 $ 378,564 equivalents Accounts 379,643 345,583 receivable, net Inventories 384,415 404,395 Prepaid expenses and 163,478 150,678 other current assets Prepaid taxes 7,078 19,566 Current assets of discontinued 479,595 639,552 operations Total current 1,844,674 1,938,338 assets Property, plant and equipment, 470,377 498,281 net Operating lease 73,666 91,817 assets Goodwill 2,288,319 2,305,050 Intangible 1,404,749 1,524,150 assets, net Deferred tax 12,772 12,593 assets Other assets 124,662 112,984 Non-current assets of 128,642 464,026 discontinued operations Total assets $ 6,347,861 $ 6,947,239 LIABILITIES AND EQUITY Current liabilities Current $ 87,500 $ 100,000 borrowings Accounts 142,869 130,201 payable Accrued 142,007 117,350 expenses Payroll and benefit-related 133,730 124,769 liabilities Accrued 16,564 5,404 interest Income taxes 194,638 18,787 payable Other current 91,524 137,195 liabilities Current liabilities of 108,270 128,320 discontinued operations Total current 917,102 762,026 liabilities Long-term 1,531,456 2,541,449 borrowings Deferred tax 168,570 183,749 liabilities Noncurrent liability for 3,682 3,536 uncertain tax positions Noncurrent operating lease 60,785 84,210 liabilities Other 161,163 194,532 liabilities Non-current liabilities of 11,387 52,969 discontinued operations Total 2,854,145 3,822,471 liabilities Commitments and contingencies Total shareholders' 3,493,716 3,124,768 equity Total liabilities and $ 6,347,861 $ 6,947,239 shareholders' equity
Nine Months September 30, September 28, Ended 2026 2025 ────────────────────────────────────────────────────────────────────────────── -Dollars in thousands Cash flows from operating activities of continuing operations: Net income $ 1,018,966 $ -191,310 Adjustments to reconcile net income to net cash provided by operating activities: (Income) loss from -927,755 253,393 discontinued operations Depreciation 53,330 39,177 expense Intangible asset 101,815 84,986 amortization expense Deferred financing costs and debt 4,224 3,181 discount amortization expense Loss on extinguishment 4,531 — of debt Changes in contingent -2,731 16,075 consideration Stock-based 18,448 19,002 compensation Asset impairment — 108,117 charge Gain on non-designated foreign — -82,636 currency forward contracts Deferred income 1,163 -37,536 taxes, net Interest benefit on swaps -23,159 -13,254 designated as net investment hedges Other -425 -4,961 Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts -40,717 -94,934 receivable Inventories 10,158 52,831 Prepaid expenses and -4,178 -24,245 other assets Accounts payable, accrued 35,422 -24,329 expenses and other liabilities Income taxes receivable and -14,258 -93,287 payable, net Net cash provided by operating 234,834 10,270 activities from continuing operations Cash flows from investing activities of continuing operations: Expenditures for property, -54,438 -71,418 plant and equipment Proceeds from sale of — 6,712 business and assets Payments for businesses and intangibles — -831,857 acquired, net of cash acquired Proceeds from non-designated — 82,203 balance sheet hedges Insurance settlement — 9,447 proceeds Net payments on swaps designated as -38,308 7,612 net investment hedges Proceeds from sales of 17 — investments Purchase of -9,000 -5,000 investments Net cash used in investing activities -101,729 -802,301 from continuing operations Cash flows from financing activities of continuing operations: Proceeds from 2,350,000 1,140,000 new borrowings Reduction in -3,368,125 -121,750 borrowings Repurchase of -554,951 -300,000 common stock Net (payments) proceeds from share based compensation -5,383 7,161 plans and related tax impacts Share repurchase -2,802 -1,894 excise tax Payments for contingent -156 -166 consideration Dividends paid -43,748 -45,242 Debt extinguishment, -16,098 -4,961 issuance and amendment fees Net cash (used in) provided by financing -1,641,263 673,148 activities from continuing operations Cash flows from discontinued operations: Net cash provided by 56,279 178,200 operating activities Net cash provided by (used in) 1,482,576 -24,481 investing activities Net cash provided by 1,538,855 153,719 discontinued operations Effect of exchange rate changes on cash, -7,036 18,824 cash equivalents and restricted cash equivalents Net increase in cash, cash equivalents 23,661 53,660 and restricted cash equivalents Cash, cash equivalents and restricted cash 453,848 327,650 equivalents at the beginning of the period Less: Cash, cash equivalents and restricted -33,181 -44,801 cash of discontinued operations Cash, cash equivalents and restricted cash $ 444,328 $ 336,509 equivalents at the end of the period
Full text with the tables
Exhibit 99.1
FOR IMMEDIATE RELEASE November 5, 2026
───────────────────────────────────────────
Teleflex Reports
Third
Quarter Finan
cial Results and Full Year 2026 Outlook
Maintaining Pro Forma Adjusted Constant Currency Revenue Growth Guidance Range
of 3.5% to 4.5%
Increasing 2026 Adjusted Diluted EPS from Continuing Operations Guidance Range
to $7.50 to $7.75
Repurchased $350 Million in Common Stock Through Accelerated Share Repurchase
and Open-Market Transactions Since July 1, 2026
Wayne, PA --
Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial
results for the third quarter ended September 30, 2026.
Third quarter 2026 continuing operations financial summary 1
• Revenue from continuing operations of $567.8 million, up 0.2% compared to the
prior year period, and up 3.0% on a pro forma adjusted constant currency basis
1,2
• GAAP diluted EPS from continuing operations of $1.30, compared to $(1.32) in
the prior year period
• Adjusted diluted EPS from continuing operations of $2.63, compared to $1.89 in
the prior year period
“We are pleased with our third quarter performance, which included margin
expansion and robust earnings per share growth, even when excluding IEEPA tariff
refunds,” said Jason Weidman, Teleflex’s President and Chief Executive Officer.
“Vascular and Surgical continued to deliver solid mid-single-digit growth, and
Interventional improved, returning to modest growth. We made notable progress on
the Interventional integration and strengthened the business’s leadership with
the addition of Jason Fontana as President and General Manager. We also reached
an important milestone in simplifying our operating model: we now manage and
report as three global business units, Vascular, Interventional and Surgical.
Reflecting our third quarter progress, we are raising our full-year adjusted
earnings per share guidance.”
Mr. Weidman continued, “We also continued to return capital to shareholders on
an accelerated timeline, repurchasing approximately $350 million of common stock
between the beginning of the third quarter and the issuance of this release,
through the completion of our $250 million accelerated share repurchase program
and an additional $100 million in open-market purchases. We remain confident in
completing the Acute Care and Interventional Urology divestiture and continue to
work toward closing by year-end, subject to completion of the regulatory
process. At the same time, we continue to invest in innovation, with programs
that have potential to become long-term growth platforms. Freesolve™, our
resorbable magnesium scaffold, received FDA Breakthrough Device Designation for
PCI, and we see EZPLAZ, the first and only FDA-licensed freeze-dried plasma, as
a potential long-term U.S. market opportunity of at least $200 million. Our
priorities are clear: strengthening our foundation by delivering our
transformation, inclusive of the completion of our Strategic Divestitures and
the Vascular Intervention integration, accelerating our organizational
effectiveness, and elevating our growth profile within a
1
balanced capital allocation framework. We expect these efforts to deliver a
meaningful step-up in adjusted earnings per share in 2027, and provide a solid
foundation for sustainable growth over time.”
2026 continuing operations guidance summary
1
• Reducing GAAP revenue growth guidance range to 13.2% to 14.2% due to changes
in foreign exchange rates
• Maintaining pro forma adjusted constant currency revenue growth guidance range
of 3.5% to 4.5% 2
• Increasing GAAP EPS from continuing operations guidance range to $2.84 to
$3.09
• Increasing Adjusted diluted EPS from continuing operations guidance range to
$7.50 to $7.75
◦ Includes an assumption of approximately 20.0% (as compared to approximately
19.0% previously) adjusted operating margin for 2026 inclusive of IEEPA tariff
refunds of $16.5 million recognized in the third quarter 2026
◦ Excludes expected benefits from transition services and manufacturing services
agreements that come into effect upon closing the Acute Care and Interventional
Urology Strategic Divestiture
◦ Reflects execution of capital allocation strategy including repayment of $700
million Term Loan A-2, reduction of revolving credit facility borrowings, and
$600 million of share repurchases, consisting of $250 million of open-market
repurchases completed in the second quarter of 2026 and, subsequently through
the date of this release, a $250 million accelerated share repurchase and an
additional $100 million of open-market repurchases
◦ Excludes other potential future repurchases under previously announced $1
billion share repurchase program primarily funded with proceeds from the
Strategic Divestitures
◦ Excludes incremental debt paydown with net proceeds from the Strategic
Divestitures
(1) Continuing operations excludes the Acute Care, Interventional Urology, and
OEM businesses that were classified as discontinued operations beginning in the
fourth quarter of 2025 as a result of our entry into agreements to divest those
businesses, which we refer to as the “Strategic Divestitures".
(2) Pro forma adjusted constant currency revenue growth includes revenue
generated by the acquired Vascular Intervention business in the prior year
period, and excludes (a) revenue generated by products previously included
within continuing operations that were discontinued at the end of 2025 due to a
strategic realignment, (b) the impact of the Italian payback measure, and (c)
the impact of foreign exchange.
STRATEGIC DIVESTITURES UPDATE
OEM Divestiture
As previously disclosed, on August 3, 2026, the Company completed the
divestiture of its OEM business to Montagu and Kohlberg, for $1.5 billion in
cash. The Company received after-tax proceeds of $1.25 billion.
Acute Care and Interventional Urology Divestiture
The Company continues to advance the pending sale of its Acute Care and
Interventional Urology businesses to Intersurgical Ltd., and the regulatory
review process is progressing. The Company continues to work toward completing
the transaction by the end of 2026. Timing remains subject to regulatory
approval and other customary closing conditions, and closing may extend into
2027.
2
CAPITAL ALLOCATION AND BALANCE SHEET ACTIVITY
Debt Reduction
In August 2026, following the completion of the OEM sale, the Company applied a
portion of the net cash proceeds to repay its $700 million term loan A-2 and a
portion of its outstanding revolving credit facility borrowings.
Share Repurchase
As previously disclosed, on December 9, 2025, the Board of Directors authorized
a share repurchase program for up to $1 billion of the Company's common stock.
From July 1, 2026 through the date of this release, the Company has repurchased
$350 million of its common stock through an ASR program and open-market
purchases. This consisted of 2.7 million shares repurchased at an average price
of $128.96 per share. These repurchases (but not any potential future
repurchases) have been taken into account in our 2026 Continuing Operations
Outlook below.
As of November 5, 2026, the Company had $400 million remaining available under
the current authorization.
IEEPA TARIFF REFUNDS
Following the U.S. Supreme Court’s February 20, 2026 decision invalidating
tariffs imposed under the International Emergency Economic Powers Act (“IEEPA”),
the Company submitted refund requests for IEEPA tariffs it had previously paid.
During the third quarter of 2026, the Company received approval and payment for
substantially all submitted requests, with total refund payments of $39.2
million, including refunds related to products associated with the Strategic
Divestiture businesses.
Of the total refund payments, the Company recognized a benefit of $25.3 million
within continuing operations, which reduced cost of sales. This benefit includes
$16.5 million and $8.8 million related to tariffs recognized in 2026 and 2025,
respectively. The refund pertaining to tariffs incurred in 2026 is included in
the Company’s non-GAAP financial measures for the third quarter of 2026.
Conversely, the refund pertaining to tariffs incurred in 2025 was excluded from
the Company’s non-GAAP financial measures for the third quarter of 2026 because
it does not represent normal, recurring operating expenses, making it difficult
to contribute to a meaningful evaluation of our period-over-period operating
performance. The Company anticipates submitting additional refund requests
during the fourth quarter under the final phase of the IEEPA tariff refund
process.
BOARD OF DIRECTORS UPDATE
Appointment of Veteran Medical Technology Executive Sean M. Salmon
On September 8, 2026, the Company announced the appointment of Sean M. Salmon to
its Board of Directors. Mr. Salmon brings more than three decades of global
leadership experience in the medical device and pharmaceutical industries,
including more than 20 years at Medtronic plc, where he most recently served as
Executive Vice President and President of its Cardiovascular Portfolio, a global
business with fiscal 2025 revenue of approximately $12.5 billion. Mr. Salmon
also serves on the Board's Growth and Operating Committee, which was established
earlier this year to support management's execution of Teleflex's strategic
transformation. With Mr. Salmon's appointment, one-third of the Board has been
refreshed in 2026.
3
REPORTABLE SEGMENTS CHANGE
During the third quarter of 2026, we changed our reportable segments from a
geographically based presentation to a global (product based) business unit
presentation. As a result, we now have the following three reportable segments:
Vascular, Interventional, and Surgical. All prior comparative periods presented
have been restated to reflect these changes.
NET REVENUE BY SEGMENT
The following tables provide information regarding net revenues in each of the
Company's reportable operating segments for the three and nine months ended
September 30, 2026 and the comparable prior year period on both a GAAP and pro
forma adjusted constant currency basis.
Th…
Mo…
En…
Se… Se…
30, 28, %
20… 20… In… / (…
──────────────────────────────────────────────────────────────────────────────
Pro
Pro Pro Fo…
Re… Fo… Re… Fo… Re… Cu… A… Ad…
Re… Ad… Ad… Re… Ad… Ad… Re… Im… I… Co…
Re… Re… Gr… Cu…
Re…
Gr…
V… $2… $— $2… $2… $— $2… 4.… 0.… —% 4.…
I… 21… — 21… 21… -5… 21… (2… (0… (… 0.…
S… 11… — 11… 10… -0… 10… 4.… (0… (… 5.…
S…
N… 56… — 56… 55… -5… 55… 1.… (0… (… 3.…
R…
O… — — — 9.0 -9… — (1… —% (… —%
C…
N… $5… $— $5… $5… -$… $5… 0.… (0… (… 3.…
R…
Ni…
Mo…
En…
Se… Se…
30, 28, %
20… 20… In… / (…
──────────────────────────────────────────────────────────────────────────────
Pro
Pro Pro Fo…
Re… Fo… Re… Fo… Re… Cu… A… Ad…
Re… Ad… Ad… Re… Ad… Ad… Re… Im… I… Co…
Re… Re… Gr… Cu…
Re…
Gr…
V… $7… $— $7… $6… $— $6… 7.… 1.… —% 5.…
I… 62… — 62… 43… 18… 61… 45… 0.… 4… 0.…
S… 33… — 33… 30… -1… 30… 8.… 1.… (… 8.…
S…
N… 1,… — 1,… 1,… 18… 1,… 19… 1.… 1… 4.…
R…
O… — — — 9.0 -9… — (1… —% (… —%
C…
N… $1… $— $1… $1… $1… $1… 18… 1.… 1… 4.…
R…
Notes: (1) Adjustments are inclusive of Vascular Intervention pro forma and
discontinued product adjustments.
(2) Adjustments are inclusive of discontinued product adjustments.
(3) In 2025, amounts reflect the impact from decreases in our reserves related
to the Italian payback measure pertaining to prior years.
See Pro Forma Adjusted Revenue by Segment table for reconciliation of
adjustments.
SEGMENT NET REVENUE BY REGION
The following table provides information regarding net revenues in each of the
Company's reportable operating segments by region for the three and nine months
ended September 30, 2026 and the comparable prior year period on a GAAP basis.
4
Three Months Nine Months
Ended Ended
September September September September 28,
30, 2026 28, 2025 30, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Reported
revenue
Vascular
North $155.6 $151.9 $469.1 $444.2
America
Rest of 87.9 80.6 257.5 233.4
World
Total 243.5 232.5 726.6 677.6
Interventi…
North 104.1 105.7 302.5 266.5
America
Rest of 106.2 110.2 324.3 163.5
World
Total 210.3 215.9 626.8 430.0
Surgical
North 64.8 63.9 191.1 179.6
America
Rest of 49.2 45.6 141.9 127.5
World
Total 114.0 109.5 333.0 307.1
Segment Net
Revenues1
North 324.5 321.5 962.7 890.3
America
Rest of 243.3 236.4 723.7 524.4
World
Total1 $567.8 $557.9 $1,686.4 $1,414.7
Note: (1) Represents Segment Net Revenues, which excludes "Other". See table
above for reconciliation of Segment Net Revenues to Consolidated Net Revenues.
5
OTHER CONTINUING OPERATIONS FINANCIAL HIGHLIGHTS
• Depreciation expense, amortization of intangible assets and deferred financing
charges for the nine months ended September 30, 2026 totaled $159.4 million
compared to $127.3 million for the prior year period.
• Total cash, cash equivalents and restricted cash equivalents at September 30,
2026 were $444.3 million compared to $402.7 million at December 31, 2025.
• Net accounts receivable at September 30, 2026 were $379.6 million compared to
$345.6 million at December 31, 2025.
• Inventories at September 30, 2026 were $384.4 million compared to $404.4
million at December 31, 2025.
2026 CONTINUING OPERATIONS OUTLOOK
On a GAAP basis, the Company reduced its full year 2026 revenue growth from
continuing operations outlook to a range of 13.2% to 14.2%. The change in
guidance range reflects our updated estimate of an approximately 0.5% positive
impact of foreign exchange rate fluctuations versus approximately 0.7%
previously. On a pro forma adjusted constant currency basis, the Company
maintained its full year 2026 revenue growth from continuing operations outlook
range of 3.5% to 4.5%.
The Company increased its full year 2026 GAAP diluted earnings per share from
continuing operations outlook to a range of $2.84 to $3.09. The Company
increased its full year 2026 adjusted diluted earnings per share from continuing
operations outlook to a range of $7.50 to $7.75.
Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations
Reconciliation
2025 2026 Guidance
Low High
GAAP revenue $1,992.7 $2,256 $2,276
Vascular Intervention
pro forma 199.0 — —
adjustment
Discontinued product -14.3 — —
adjustment
Italian payback -9.0 — —
measure adjustment
Pro forma adjusted $2,168.4 $2,256 $2,276
revenue
Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From
Continuing Operations Reconciliation
Low High
Forecasted 2026 GAAP revenue growth 13.2% 14.2%
Vascular Intervention pro forma 10.0% 10.0%
adjustment
Discontinued product adjustment (0.7)% (0.7)%
Italian payback measure adjustment (0.5)% (0.5)%
Base year adjustment (GAAP versus pro 0.4% 0.4%
forma adjusted)
Estimated impact of foreign currency 0.5% 0.5%
exchange rate fluctuations
Forecasted 2026 pro forma adjusted 3.5% 4.5%
constant currency revenue growth
6
Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations
Reconciliation
Low High
Forecasted GAAP diluted earnings per $2.84 $3.09
share from continuing operations
Restructuring and optimization items, $0.93 $0.93
net of tax
Acquisition, integration and divestiture $0.58 $0.58
related items, net of tax
Other items, net of tax $(0.46) $(0.46)
ERP implementation, net of tax $0.31 $0.31
MDR, net of tax $0.02 $0.02
Intangible amortization expense, net of $2.78 $2.78
tax
Tax adjustments $0.50 $0.50
Forecasted adjusted diluted earnings per
share from continuing operations, net of $7.50 $7.75
tax
7
CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION
A webcast of Teleflex's third quarter 2026 investor conference call can be
accessed live from a link on the Company's website at teleflex.com. The call
will begin at 8:00 am ET on November 5, 2026.
An audio replay of the investor call will be available beginning at 11:00 am ET
on November 5, 2026 , either on the Teleflex website or by telephone. The call
can be accessed by dialing 1 833 309 1852 (U.S. and Canada) or 1 929 828
5978(all other locations). The confirmation code is 893 259 060.
ADDITIONAL NOTES
References in this release to the impact of foreign currency exchange rate
fluctuations on adjusted diluted earnings per share include both the impact of
translating foreign currencies into U.S. dollars and the impact of foreign
currency exchange rate fluctuations on foreign currency denominated
transactions.
In the discussion of segment results, "new products" refers to products for
which we initiated commercial sales within the past 36 months and "existing
products" refers to products we have sold commercially for more than 36 months.
Pro forma adjusted revenue and pro forma adjusted constant currency revenue
growth give effect to, among other things, our acquisition of the Vascular
Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on
January 1, 2025. The pro forma information is presented for informational
purposes only and is not necessarily indicative of the historical results that
would have occurred under our ownership and management, nor the results that may
be obtained in the future.
Certain financial information is presented on a rounded basis, which may cause
minor differences. Segment results and commentary exclude the impact of
discontinued operations.
NOTES ON NON-GAAP FINANCIAL MEASURES
We report our financial results in accordance with accounting principles
generally accepted in the United States, commonly referred to as “GAAP”. In this
press release, we provide supplemental information, consisting of the following
non-GAAP financial measures: pro forma adjusted revenues, pro forma adjusted
constant currency revenue growth, and adjusted diluted earnings per share. These
non-GAAP measures are described in more detail below. Management uses these
financial measures to assess Teleflex’s financial performance, make operating
decisions, allocate financial resources, provide guidance on possible future
results, and assist in its evaluation of period-to-period and peer comparisons.
The non-GAAP measures may be useful to investors because they provide insight
into management’s assessment of our business, and provide supplemental
information pertinent to a comparison of period-to-period results of our ongoing
operations. The non-GAAP financial measures are presented in addition to results
presented in accordance with GAAP and should not be relied upon as a substitute
for GAAP financial measures. Moreover, our non-GAAP financial measures may not
be comparable to similarly titled measures used by other companies.
Pro forma adjusted revenue: This non-GAAP measure is based upon net revenues,
adjusted to (i) exclude products discontinued in the year ended December 31,
2025 due to a strategic realignment; (ii) exclude the items described in
8
Italian payback measure; and (iii) give effect to our acquisition of the
Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred
on January 1, 2025.
Pro forma adjusted constant currency revenue growth: This non-GAAP measure is
based upon net revenues, adjusted to exclude, depending on the period presented,
the items described in Pro forma adjusted revenue and to eliminate the impact of
translating the results of international subsidiaries at different currency
exchange rates from period to period. The impact of changes in foreign currency
may vary significantly from period to period, and such changes generally are
outside of the control of our management. We believe that this measure
facilitates a comparison of our operating performance exclusive of currency
exchange rate fluctuations that do not reflect our underlying performance or
business trends.
Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted
earnings per share from continuing operations, the most directly comparable GAAP
measure, adjusted to exclude, depending on the period presented, the items
described below. Management does not believe that any of the excluded items are
indicative of our underlying core performance or business trends.
Restructuring and optimization charges - Restructuring and optimization charges
include expenses associated with discrete initiatives designed to, among other
things, consolidate or relocate manufacturing, administrative and other
facilities, outsource distribution operations, improve operating efficiencies,
integrate acquired businesses and optimize product portfolios through targeted
optimization efforts. These charges include qualified restructuring costs (which
may include costs associated with employee termination, contract termination,
facility closure, employee relocation, equipment relocation, outplacement),
restructuring related (which may include accelerated depreciation expense
related to facility closures, costs to transfer manufacturing operations between
locations, and retention bonuses offered to certain employees as an incentive
for them to remain with our company after completion of a restructuring program)
and product line exit charges.
Impairment charges - Impairment charges, including those related to goodwill,
and other assets occur if, due to events or changes in circumstances, we
determine that the carrying value of an asset exceeds its fair value. Impairment
charges do not directly affect our liquidity, but could have a material adverse
effect on our reported financial results.
Acquisition, integration and divestiture related items - Acquisition and
integration expenses are incremental charges, other than restructuring or
restructuring related expenses, that are directly related to specific business
or asset acquisition transactions. These charges may include, among other
things, professional, consulting and other fees; systems integration costs;
inventory step-up amortization (amortization, through cost of goods sold, of the
increase in fair value of inventory resulting from a fair value calculation as
of the acquisition date); fair value adjustments to contingent consideration
liabilities; temporary financing costs directly associated with the transaction,
such as bridge loan financing fees, ticking fees, and similar charges, and the
impact of derivative instruments executed to hedge foreign currency exposure or
other risks associated with the purchase price. Divestiture related activities
involve specific business or asset sales. Depending primarily on the terms of a
divestiture transaction, the carrying value of the divested business or assets
on our financial statements and other costs we incur as a direct result of the
divestiture transaction, we may recognize a gain or loss in connection with the
divestiture related activities.
9
S eparation costs - These are expenses related to the Strategic Divestitures,
including activities to prepare the businesses for divestiture and maintain
continuity through the separation process. These charges and costs do not
represent normal and recurring operating expenses, will be inconsistent in
amounts and frequency, and are not expected to recur after the transaction and
related transition services agreements and other arrangements negotiated in
connection with the Strategic Divestitures have been completed.
Italian payback measure - The Italian payback measure is a law that requires
suppliers of medical devices to the Italian National Healthcare System to make
payments to the Italian government if medical device expenditures in a given
year exceed regional expenditure ceilings established for that year. As a result
of a ruling from the Italian courts, we recognized a decrease in our reserves
during the year ended December 31, 2024, of which $13.8 million related to prior
years when including discontinued operations and $6.2 million on a continuing
operations basis. In August 2025, the Italian Parliament enacted a modification
to the previously enacted legislation that reduced the payment amounts due from
the affected companies, including Teleflex, to approximately 25% of the amounts
originally invoiced for the years 2015 through 2018. As a result of the
modification in the legislation, along with an adjustment to our calculation of
the reserves related to years 2019 through 2025, we recognized a $23.7 million
decrease in our reserve (and corresponding increase to revenue for the year
ended December 31, 2025), of which $20.1 million pertains to prior periods when
including discontinued operations and $9.0 million on a continuing operations
basis. The amounts do not represent normal adjustments to revenue and are
nonrecurring in nature, making it difficult to contribute to a meaningful
evaluation of our period over period operating performance.
Other - These are discrete items that occur sporadically and can affect period-
to-period comparisons.
European medical device regulation - The European Union (“EU”) has adopted the
EU Medical Device Regulation (“MDR”), which replaces the existing Medical
Devices Directive (“MDD”) and imposes more stringent requirements for the
marketing and sale of medical devices in the EU, including requirements
affecting clinical evaluations, quality systems and post-market surveillance.
The MDR requirements became effective in May 2021, although certain devices that
previously satisfied MDD requirements can continue to be marketed in the EU
until December 2027 for highest-risk devices and December 2028 for lower-risk
devices, subject to certain limitations. Significantly, the MDR will require the
re-registration of previously approved medical devices. As a result, Teleflex
will incur expenditures in connection with the new registration of medical
devices that previously had been registered under the MDD. Therefore, these
expenditures are not considered to be ordinary course expenditures in connection
with regulatory matters (in contrast, no adjustment has been made to exclude
expenditures related to the registration of medical devices that were not
registered previously under the MDD).
Intangible amortization expense - Certain intangible assets, including customer
relationships, intellectual property, distribution rights, trade names and non-
competition agreements, initially are recorded at historical cost and then
amortized over their respective estimated useful lives. The amount of such
amortization can vary from period to period as a result of, among other things,
business or asset acquisitions or dispositions.
10
ERP implementation - These adjustments represent direct and incremental costs
incurred in connection with our implementation of a new global enterprise
resource planning ("ERP") solution and related IT transition costs. An
implementation of this scale is a significant undertaking and will require
substantial time and attention of management and key employees. The associated
costs do not represent normal and recurring operating expenses and will be
inconsistent in amounts and frequency making it difficult to contribute to a
meaningful evaluation of our operating performance.
Tax adjustments - These adjustments represent the impact of the expiration of
applicable statutes of limitations for prior year returns, the resolution of
audits, the filing of amended returns with respect to prior tax years and/or tax
law or certain other discrete changes affecting our deferred tax liability.
PRO FORMA ADJUSTED REVENUE BY SEGMENT
The following table provides information regarding pro forma adjusted revenues
in each of the Company's reportable operating segments in continuing operations
for the three and nine months ended September 30, 2026 and the comparable prior
year periods .
Three Months Nine Months
Ended Ended
September September September September 28,
30, 2026 28, 2025 30, 2026 2025
──────────────────────────────────────────────────────────────────────────────
Vascular 243.5 232.5 726.6 677.6
Interventi… 210.3 215.9 626.8 430.0
Surgical 114.0 109.5 333.0 307.1
Other — 9.0 — 9.0
GAAP 567.8 566.9 1,686.4 1,423.7
revenue
Interventi…
- Vascular — — — 199.0
Interventi…
Interventi…
- — -5.0 — -10.8
Discontinu…
Products
Surgical -
Discontinu… — -0.7 — -1.5
Products
Other -
Italian — -9.0 — -9.0
Payback
Measure
Pro forma
adjusted $567.8 $552.2 $1,686.4 $1,601.4
revenue
Vascular 243.5 232.5 726.6 677.6
Interventi… 210.3 210.9 626.8 618.2
Surgical 114.0 108.8 333.0 305.6
11
Reconciliation of Consolidated Statement of Income Items (Dollars in millions,
except per share data)
Th…
Mo…
En…
Se…
30,
20…
──────────────────────────────────────────────────────────────────────────────
Dilu…
Inc… Eff… earn…
Gro… Ope… bef… Inc… inc… per
Rev… mar… SG&… R&D… mar… inc… tax tax share
tax… exp… rate from
cont…
oper…
GA…
Ba…
- $56… 65.… 38.… 7.6% 18.… $83… $28… 34.… $1.30
Co…
Op…
Ad…
Re…
and
op… — 0.1 -0.5 — 0.5 3.7 0.7 0.09
ch…
(A)
Ac…
in…
and
di… — — -0.7 — 0.7 4.3 0.9 0.08
re…
it…
(B)
Ot…
it… — -1.5 — — -1.5 -5.3 -0.4 -0.12
(C)
ERP — — -0.6 — 0.6 3.3 0.5 0.07
im…
MDR — — — -0.1 0.1 0.1 — —
In…
am… — 3.2 -2.8 — 6.0 33.9 4.5 0.70
ex…
Tax — — — — — — -21… 0.51
ad…
Ad… — 1.8 -4.6 -0.1 6.4 40.0 -15… 1.33
to…
Ad… $56… 66.… 34.… 7.5% 25.… $12… $13… 11.… $2.63
ba…
Th…
Mo…
En…
Se…
28,
20…
──────────────────────────────────────────────────────────────────────────────
Dilu…
(Lo… (los…
Inc… Inc… Eff… earn…
Rev… Gro… SG&… R&D… Ope… bef… tax inc… per
mar… mar… inc… exp… tax share
tax… rate from
cont…
oper…
GA…
Ba…
- $56… 51.… 36.… 7.8% (11… $(9… $(3… 36.… $(1.…
Co…
Op…
Ad…
Re…
and
op… — 0.6 — — 0.9 4.8 0.8 0.08
ch…
(A)
Im… — — — — 17.6 100… 22.9 1.74
ch…
Ac…
in…
and
di… — 7.4 -1.1 -0.1 8.6 48.7 9.4 0.88
re…
it…
(B)
Se… — — — — 0.2 1.3 0.1 0.03
co…
It…
pa… -9.0 -0.6 0.5 0.1 -1.2 -9.0 -0.9 -0.18
me…
(D)
ERP — — -0.6 — 0.6 3.6 0.6 0.07
im…
MDR — — — -0.2 0.2 1.3 — 0.03
In…
am… — 3.4 -2.7 — 6.1 34.3 4.7 0.67
ex…
Tax — — — — — — 5.0 -0.11
ad…
Ad… -9.0 10.8 -3.9 -0.2 33.0 185… 42.6 3.21
to…
Ad… $55… 62.… 32.… 7.6% 22.… $92… $8.6 9.3% $1.89
ba…
12
Ni…
Mo…
En…
Se…
30,
20…
──────────────────────────────────────────────────────────────────────────────
Dilu…
Inc… Eff… earn…
Gro… Ope… bef… Inc… inc… per
Rev… mar… SG&… R&D… mar… inc… tax tax share
tax… exp… rate from
cont…
oper…
GA…
Ba…
- $1,… 59.… 39.… 7.9% 11.… $12… $33… 26.… $2.11
Co…
Op…
Ad…
Re…
and
op… — 0.4 -1.1 — 2.4 42.5 6.9 0.83
ch…
(A)
Ac…
in…
and
di… — 0.5 -1.1 — 1.6 27.2 5.9 0.49
re…
it…
(B)
Ot…
it… — -0.5 1.2 — -1.7 -24… -4.4 -0.47
(C)
ERP — — -0.7 — 0.7 11.3 1.8 0.22
im…
MDR — — — -0.1 0.1 0.9 — 0.02
In…
am… — 3.1 -2.9 — 6.0 101… 13.7 2.04
ex…
Tax — — — — — — -21… 0.49
ad…
Ad… — 3.5 -4.6 -0.1 9.1 159… 2.7 3.62
to…
Ad… $1,… 63.… 34.… 7.8% 20.… $28… $35… 12.… $5.73
ba…
Ni…
Mo…
En…
Se…
28,
20…
──────────────────────────────────────────────────────────────────────────────
Dilu…
Inc… Eff… earn…
Gro… Ope… bef… Inc… inc… per
Rev… mar… SG&… R&D… mar… inc… tax tax share
tax… exp… rate from
cont…
oper…
GA…
Ba…
- $1,… 57.… 35.… 6.7% 7.3% $37… $(2… (67… $1.38
Co…
Op…
Ad…
Re…
and
op… — 1.0 — — 1.3 18.4 3.1 0.35
ch…
(A)
Im… — — — — 7.6 108… 24.7 1.86
ch…
Ac…
in…
and
di… — 3.0 2.8 — 0.3 2.6 12.2 -0.21
re…
it…
(B)
Se… — — — — 0.2 2.6 0.1 0.06
co…
It…
pa… -9.0 -0.2 0.1 — -0.6 -8.9 -0.9 -0.18
me…
ERP — — -0.9 — 0.9 13.3 2.1 0.25
im…
MDR — — — -0.2 0.2 2.9 0.1 0.06
In…
am… — 3.2 -2.7 — 6.0 85.0 10.8 1.65
ex…
Tax — — — — — — 7.1 -0.16
ad…
Ad… -9.0 7.0 -0.7 -0.2 15.9 224… 59.3 3.68
to…
Ad… $1,… 64.… 34.… 6.5% 23.… $26… $34… 13.… $5.06
ba…
Notes: (1) Selling, general and administrative expenses and research and
development expenses are shown as a percentage of as reported and adjusted
revenues.
(2) Operating margin defined as Income from continuing operations before
interest, loss on extinguishment of debt and taxes as a percentage of as
reported and adjusted revenues.
Totals may not sum due to rounding .
13
Tickmarks to Reconciliation Tables
(A)
Restructuring and optimization charges –
For the three months ended September 30, 2026, a pre-tax restructuring benefit
of $0.3 million was offset by restructuring related charges of $4.0 million. For
the three months ended September 28, 2025, pre-tax restructuring charges were
$1.6 million and restructuring related charges were $3.3 million. For the nine
months ended September 30, 2026, pre-tax restructuring charges were $16.7
million and restructuring related charges were $25.9 million. For the nine
months ended September 28, 2025, pre-tax restructuring charges were $4.3
million, restructuring related charges were $11.5 million, and product
optimization charges were $2.6 million.
(B) Acquisition, integration and divestiture related items – For the three and
nine months ended September 30, 2026, these charges primarily related to the
acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG. For
the three months ended September 30, 2026 these charges included acquisition and
integration costs of $4.2 million. For the nine months ended September 30, 2026
these charges included acquisition and integration costs of $20.9 million and
inventory step up costs of $8.0 million. For the three and nine months ended
September 28, 2025, these charges primarily related to the acquisition of the
Vascular Intervention business of BIOTRONIK SE & Co. KG and changes in the
estimated fair value of our contingent consideration liabilities. For the three
months ended September 28, 2025 the charges included inventory step-up costs of
$42.1 million and integration and acquisition costs of $4.4 million. For the
nine months ended September 28, 2025 the charges included inventory step-up
costs of $42.1 million and acquisition and integration costs of $26.5 million,
which were offset by a benefit of $82.2 million related to non-designated
foreign currency forward contracts.
(C)
Other –
For the three months ended September 30, 2026, other items included a benefit
from IEEPA tariff refunds of $8.8 million partially offset by legal and advisory
fees incurred in response to an activist investor campaign of $0.1 million and a
loss on extinguishment of debt of $3.4 million. For the nine months ended
September 30, 2026, other items included a benefit from a litigation settlement
of $25.0 million and IEEPA tariff refunds of $8.8 million partially offset by
legal and advisory fees incurred in response to an activist investor campaign of
$3.7 million, a loss on extinguishment of debt of $4.5 million, and charges
incurred in connection with the credit agreement refinancing of $1.0 million.
14
ABOUT TELEFLEX INCORPORATED
As a global provider of medical technologies, Teleflex is driven by our purpose
to improve the health and quality of people’s lives. Through our vision to
become the most trusted partner in healthcare, we offer a diverse portfolio with
solutions in the therapy areas of anesthesia, emergency medicine, interventional
cardiology and radiology, surgical, vascular access, and urology. We believe
that the potential of great people, purpose driven innovation, and world-class
products can shape the future direction of healthcare.
Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™,
Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.
At Teleflex, we are empowering the future of healthcare. For more information,
please visit teleflex.com.
CAUTION CONCERNING FORWARD-LOOKING INFORMATION
This press release contains forward-looking statements, including, but not
limited to, the implementation and execution of our share repurchase program;
our intended use of proceeds from the OEM divestiture; our expectations with
respect to our financial profile in 2027 and beyond; forecasted 2026 GAAP and
pro forma adjusted revenue, GAAP and pro forma adjusted constant currency
revenue growth and GAAP and adjusted diluted earnings per share; and our
estimates regarding the projected impact of foreign currency exchange rate
fluctuations on our 2026 financial results. Actual results could differ
materially from those in the forward-looking statements due to, among other
things, unanticipated difficulties and expenditures in connection with
integration programs; the possibility that the remaining pending transaction in
our Strategic Divestitures does not close; unanticipated costs and length of
time required to comply with legal requirements and regulatory approvals
applicable to the Strategic Divestitures; customer and shareholder reaction to
the Strategic Divestitures; disruption from the Strategic Divestitures that may
make it more difficult to maintain business and operational relationships;
significant transaction costs; delays or cancellations in shipments; demand for
and market acceptance of new and existing products; our inability to provide
products to our customers, which may be due to, among other things, events that
impact key distributors, suppliers and third-party vendors that sterilize our
products; risks relating to the activities of activist stockholders; our
inability to effectively execute our restructuring plans and programs; our
inability to realize anticipated savings from restructuring plans and programs;
the impact of healthcare reform legislation and proposals to amend, replace or
repeal the legislation; changes in Medicare, Medicaid and third party coverage
and reimbursements; the impact of enacted tax legislation and related
regulations; competitive market conditions and resulting effects on revenues and
pricing; increases in raw material costs that cannot be recovered in product
pricing; global economic factors, including currency exchange rates, interest
rates, trade disputes, tariffs, sovereign debt issues and international
conflicts and hostilities, such as the ongoing conflicts in Ukraine and the
Middle East; public health epidemics; difficulties in entering new markets;
general economic conditions; and other factors described or incorporated in our
filings with the Securities and Exchange Commission, including our most recently
filed Annual Report on Form 10-K. We expressly disclaim any obligation to update
forward-looking statements, except as otherwise specifically stated by us or as
required by law or regulation.
15
TELEFLEX INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three Septem… Septem… Nine Septem…
Months 30, 28, Months 30, Septemb…
Ended 2026 2025 Ended 2026 28, 2025
──────────────────────────────────────────────────────────────────────────────
-Dolla…
and
shares
in
thousa…
except
per
share
Net $ 567,783 $ 566,946 $ 1,686,… $ 1,423,7…
reven…
Cost
of 198,995 274,900 678,456 610,422
goods
sold
Gross 368,788 292,046 1,007,… 813,307
profit
Selli…
gener…
and 220,724 207,381 660,251 497,800
admin…
expen…
Resea…
and 42,983 44,261 132,491 96,044
devel…
expen…
Restr…
(cred…
charg…
separ… -346 102,841 16,745 114,963
costs
and
impai…
charg…
Income
(loss)
from
conti…
opera…
before
inter… 105,427 -62,437 198,434 104,500
taxes
and
loss
on
extin…
of
debt
Inter… 21,206 31,833 74,877 72,073
expen…
Inter… -2,282 -1,832 -5,406 -4,549
income
Loss
on
extin… 3,381 — 4,531 —
of
debt
Income
(loss)
from
conti… 83,122 -92,438 124,432 36,976
opera…
before
taxes
Taxes
(bene…
on
income 28,835 -34,013 33,221 -25,107
from
conti…
opera…
Income
(loss)
from 54,287 -58,425 91,211 62,083
conti…
opera…
Income
(loss)
from
disco… 1,090,… -346,1… 1,148,… -231,519
opera…
before
taxes
Taxes
on
income
(loss) 217,332 4,311 220,328 21,874
from
disco…
opera…
Income
(loss)
from 873,140 -350,4… 927,755 -253,393
disco…
opera…
Net
income $ 927,427 $ -408,8… $ 1,018,… $ -191,310
(loss)
Earni…
per
share:
Basic:
Income
(loss)
from $ 1.31 $ -1.32 $ 2.12 $ 1.39
conti…
opera…
Income
(loss)
from 21.05 -7.92 21.53 -5.66
disco…
opera…
Net
income $ 22.36 $ -9.24 $ 23.65 $ -4.27
(loss)
Dilut…
Income
(loss)
from $ 1.30 $ -1.32 $ 2.11 $ 1.38
conti…
opera…
Income
(loss)
from 20.98 -7.92 21.47 -5.65
disco…
opera…
Net
income $ 22.28 $ -9.24 $ 23.58 $ -4.27
(loss)
Weigh…
avera…
common
shares
outst…
Basic 41,484 44,237 43,091 44,755
Dilut… 41,628 44,237 43,210 44,850
16
TELEFLEX INCORPORATED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
-Dollars in
thousands
ASSETS
Current assets
Cash and cash $ 430,465 $ 378,564
equivalents
Accounts 379,643 345,583
receivable, net
Inventories 384,415 404,395
Prepaid
expenses and 163,478 150,678
other current
assets
Prepaid taxes 7,078 19,566
Current assets
of discontinued 479,595 639,552
operations
Total current 1,844,674 1,938,338
assets
Property, plant
and equipment, 470,377 498,281
net
Operating lease 73,666 91,817
assets
Goodwill 2,288,319 2,305,050
Intangible 1,404,749 1,524,150
assets, net
Deferred tax 12,772 12,593
assets
Other assets 124,662 112,984
Non-current
assets of 128,642 464,026
discontinued
operations
Total assets $ 6,347,861 $ 6,947,239
LIABILITIES AND
EQUITY
Current
liabilities
Current $ 87,500 $ 100,000
borrowings
Accounts 142,869 130,201
payable
Accrued 142,007 117,350
expenses
Payroll and
benefit-related 133,730 124,769
liabilities
Accrued 16,564 5,404
interest
Income taxes 194,638 18,787
payable
Other current 91,524 137,195
liabilities
Current
liabilities of 108,270 128,320
discontinued
operations
Total current 917,102 762,026
liabilities
Long-term 1,531,456 2,541,449
borrowings
Deferred tax 168,570 183,749
liabilities
Noncurrent
liability for 3,682 3,536
uncertain tax
positions
Noncurrent
operating lease 60,785 84,210
liabilities
Other 161,163 194,532
liabilities
Non-current
liabilities of 11,387 52,969
discontinued
operations
Total 2,854,145 3,822,471
liabilities
Commitments and
contingencies
Total
shareholders' 3,493,716 3,124,768
equity
Total
liabilities and $ 6,347,861 $ 6,947,239
shareholders'
equity
17
TELEFLEX INCORPORATED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine Months September 30, September 28,
Ended 2026 2025
──────────────────────────────────────────────────────────────────────────────
-Dollars in
thousands
Cash flows from
operating
activities of
continuing
operations:
Net income $ 1,018,966 $ -191,310
Adjustments to
reconcile net
income to
net cash
provided by
operating
activities:
(Income) loss
from -927,755 253,393
discontinued
operations
Depreciation 53,330 39,177
expense
Intangible
asset 101,815 84,986
amortization
expense
Deferred
financing costs
and debt 4,224 3,181
discount
amortization
expense
Loss on
extinguishment 4,531 —
of debt
Changes in
contingent -2,731 16,075
consideration
Stock-based 18,448 19,002
compensation
Asset
impairment — 108,117
charge
Gain on
non-designated
foreign — -82,636
currency
forward
contracts
Deferred income 1,163 -37,536
taxes, net
Interest
benefit on
swaps -23,159 -13,254
designated as
net investment
hedges
Other -425 -4,961
Changes in
assets and
liabilities,
net
of effects of
acquisitions
and disposals:
Accounts -40,717 -94,934
receivable
Inventories 10,158 52,831
Prepaid
expenses and -4,178 -24,245
other assets
Accounts
payable,
accrued 35,422 -24,329
expenses and
other
liabilities
Income taxes
receivable and -14,258 -93,287
payable, net
Net cash
provided by
operating 234,834 10,270
activities from
continuing
operations
Cash flows from
investing
activities of
continuing
operations:
Expenditures
for property, -54,438 -71,418
plant and
equipment
Proceeds from
sale of — 6,712
business and
assets
Payments for
businesses and
intangibles — -831,857
acquired, net
of cash
acquired
Proceeds from
non-designated — 82,203
balance
sheet hedges
Insurance
settlement — 9,447
proceeds
Net payments on
swaps
designated as -38,308 7,612
net
investment
hedges
Proceeds from
sales of 17 —
investments
Purchase of -9,000 -5,000
investments
Net cash used
in investing
activities -101,729 -802,301
from continuing
operations
Cash flows from
financing
activities of
continuing
operations:
Proceeds from 2,350,000 1,140,000
new borrowings
Reduction in -3,368,125 -121,750
borrowings
Repurchase of -554,951 -300,000
common stock
Net (payments)
proceeds from
share based
compensation -5,383 7,161
plans and
related tax
impacts
Share
repurchase -2,802 -1,894
excise tax
Payments for
contingent -156 -166
consideration
Dividends paid -43,748 -45,242
Debt
extinguishment, -16,098 -4,961
issuance and
amendment fees
Net cash (used
in) provided by
financing -1,641,263 673,148
activities from
continuing
operations
Cash flows from
discontinued
operations:
Net cash
provided by 56,279 178,200
operating
activities
Net cash
provided by
(used in) 1,482,576 -24,481
investing
activities
Net cash
provided by 1,538,855 153,719
discontinued
operations
Effect of
exchange rate
changes on
cash, -7,036 18,824
cash
equivalents and
restricted cash
equivalents
Net increase in
cash, cash
equivalents 23,661 53,660
and restricted
cash
equivalents
Cash, cash
equivalents and
restricted
cash 453,848 327,650
equivalents at
the beginning
of the
period
Less:
Cash, cash
equivalents and
restricted -33,181 -44,801
cash of
discontinued
operations
Cash, cash
equivalents and
restricted
cash $ 444,328 $ 336,509
equivalents at
the end of the
period
18
Contacts:
Teleflex Incorporated:
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investors.teleflex.com
610-948-2836
19